medigraphic.com
ISSN 2954-3835 (Digital)
ISSN 2683-2828 (Impreso)

2020, Número S3

<< Anterior Siguiente >>

Cardiovasc Metab Sci 2020; 31 (S3)


Recomendaciones para la atención de pacientes con diabetes mellitus con factores de riesgo o enfermedad cardiovascular establecida y SARS-CoV-2

Gutiérrez-Fajardo P, Alcocer-Gamba MA, Sosa-Caballero A, Cabrera-Rayo A, Faradji-Hazán RN, Padilla-Padilla FG, Garnica-Cuellar JC, Hernández-Arispe LM, Reyes-Cianeros FA, León-Suárez A, de-Jesús-Rivera J, Mancillas-Adame L, Gaxiola-Macías M, Márquez-Rodríguez E, Miranda-Malpica E, Sánchez-Pedraza V, Lara-Martínez DS, Segovia-Palomo A, Nava-Hernández Á, Rivera-Reyes R

Idioma: Inglés [English version]
Referencias bibliográficas: 37
Paginas: 247-254
Archivo PDF: 197.37 Kb.


RESUMEN

Este trabajo contiene una revisión sobre el riesgo de los pacientes que padecen diabetes mellitus dentro del contexto de morbimortalidad general y su relación con la infección por coronavirus tipo 2 del síndrome respiratorio agudo grave (SARS-CoV-2). Asimismo, se repasan las recomendaciones generales, las de alimentación y las de prevención de las comorbilidades que más frecuentemente padecen dichos enfermos. Finalmente, se hace una revisión de las recomendaciones farmacológicas, tanto orales como parenterales, en el paciente ambulatorio, durante la hospitalización y en pacientes estados críticos infectados por SARS-CoV-2.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395: 507-513.

  2. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323: 1061-1069.

  3. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020; 109 (5): 531-538.

  4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2020. American Diabetes Association. Diabetes Care. 2020; 43 (Suppl 1): S37-S47.

  5. Akbar DH. Bacterial pneumonia: comparison between diabetics and non-diabetics. Acta Diabet. 2001; 38 (2): 77-82.

  6. García Hernández RA, Rivero Seriel L, Aroche Aportela R, Aldama Pérez LI, Hernández Navas M. COVID-19: en torno al sistema cardiovascular. Anales de la Academia de Ciencias de Cuba. 2020; 10 (2).

  7. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8 (5): 475-481.

  8. Rojas-Martínez R, Basto-Abreu A, Aguilar-Salinas CA, Zárate-Rojas E, Villalpando S, Barrientos-Gutiérrez T. Prevalencia de diabetes por diagnóstico médico previo en México. Salud Pública Mex. 2018; 60: 224-232.

  9. Hill MA, Mantzoros C, Sowers JR. COVID-19 in patients with diabetes. Metabolism. 2020; 107: 154217.

  10. Klonoff DC, Umpierrez GE. COVID-19 in patients with diabetes: risk factors that increase morbidity. Metabolism. 2020; 154224. doi: 10.1016/j.metabol.2020.154224. [Epub ahead of print].

  11. Wang W, Lu J, Gu W, Zhang Y, Liu J, Ning G. Care for diabetes with COVID-19: Advice from China. J Diabetes. 2020; 12 (5): 417-419.

  12. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395 (10229): 1054-1062.

  13. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. Diabetes Res Clin Pract. 2020; 162: 108142. doi: 10.1016/j.diabres.2020.108142. [Epub ahead of print].

  14. Vaninov N. In the eye of the COVID-19 cytokine storm. Nat Rev Immunol. 2020; 20 (5): 277.

  15. Buonaguro FM, Ascierto PA, Buonaguro L, Morse GD, Tornesello ML, Puzanov I et al. COVID-19: A paradigm change. Disponible en: https://ssrn.com/abstract=3561224 or http://dx.doi. org/10.2139/ssrn.3561224.

  16. Chen C, Zhang XR, Ju ZY, He WF. Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies. Zhonghua Shao Shang Za Zhi. 2020; 36 (0): E005. doi: 10.3760/cma.j.cn501120-20200224-00088. [Epub ahead of print].

  17. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39: 3021-3104.

  18. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018; 71 (19): e127-e248.

  19. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019; 73 (24): 3168-3209.

  20. Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr. 2020; 14 (3) :211-212.

  21. Diabetes Canada Clinical Practice Guidelines Expert Committee, Imran SA, Agarwal G, Bajaj HS, Ross S. Targets for glycemic control. Can J Diabetes. 2018; 42 Suppl 1: S42-S46.

  22. American Diabetes Association. Introduction: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020; 43 (Suppl 1): S1-S2.

  23. Carboni E, Carta AR, Carboni E. Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19? Med Hypotheses. 2020; 140: 109776. doi: 10.1016/j.mehy.2020.109776 [Epub ahead of print].

  24. Kutsukake M, Matsutani T, Tamura K, Matsuda A, Kobayashi M, Tachikawa E et al. Pioglitazone attenuates lung injury by modulating adipose inflammation. J Surg Res. 2014; 189 (2): 295-303.

  25. Xie X, Sinha S, Yi Z, Langlais PR, Madan M, Bowen BP et al. Role of adipocyte mitochondria in inflammation, lipemia and insulin sensitivity in humans: effects of pioglitazone treatment. Int J Obes (Lond). 2017 Aug 14. doi: 10.1038/ijo.2017.192. [Epub ahead of print].

  26. Bornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020 Apr 23. doi: 10.1016/S2213-8587(20)30152-2. [Epub ahead of print].

  27. Hulst AH, Plummer MP, Hollmann MW, DeVries JH, Preckel B, Deane AM et al. Systematic review of incretin therapy during peri-operative and intensive care. Crit Care. 2018; 22 (1): 299.

  28. Lee MY, Fraser JD, Chapman MJ, Sundararajan K, Umapathysivam MM, Summers MJ et al. The effect of exogenous glucose-dependent insulinotropic polypeptide in combination with glucagon-like peptide-1 on glycemia in the critically ill. Diabetes Care. 2013; 36: 3333-3336.

  29. Pasquel FJ, Fayfman M, Umpierrez GE. Debate on insulin vs non-insulin use in the hospital setting: Is it time to revise the guidelines for the management of inpatient diabetes? Curr Diab Rep. 2019; 19: 65.

  30. Hulst AH, Visscher MJ, Godfried MB, Thiel B, Gerritse BM, Scohy TV et al. Liraglutide for perioperative management of hyperglycaemia in cardiac surgery patients: a multicenter randomized superiority trial. Diabetes Obes Metab. 2020; 22: 557-565.

  31. Fayfman M, Galindo RJ, Rubin DJ, Mize DL, Anzola I, Urrutia MA et al. A randomized controlled trial on the safety and efficacy of exenatide therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes. Diabetes Care. 2019; 42: 450-456.

  32. Lu M, Zuo Y, Guo J, Wen X, Kang Y. Continuous glucose monitoring system can improve the quality of glucose control and glucose variability compared with point-of-care measurement in critically ill patients: A randomized controlled trial. Medicine (Baltimore). 2018; 97: e12138.

  33. Hansen TK, Thiel S, Wouters PJ, Christiansen JS, van den Berghe G. Intensive insulin therapy exerts anti-inflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab. 2003; 88 (3): 1082-1088.

  34. Hamblin PS, Wong R, Ekinci EI, Fourlanos S, Shah S, Jones AR et al. SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission. J Clin Endocrinol Metab. 2019; 104 (8): 3077-3087.

  35. Cameron AR, Morrison VL, Levin D, Mohan M, Forteath C, Beall C et al. Anti-inflammatory effects of metformin irrespective of diabetes status. Circ Res. 2016; 119 (5): 652-665.

  36. Barazzoni R, Bischoff SC, Breda J, Wickramasinghe K, Krznaric Z, Nitzan D et al. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection. Clin Nutr. 2020 Mar 31. doi: 10.1016/j.clnu.2020.03.022. [Epub ahead of print].

  37. Giustina A, Adler RA, Binkley N, Bouillon R, Ebeling PR, Lazaretti-Castro M et al. Controversies in vitamin D: summary statement from an international conference. J Clin Endocrinol Metab. 2019; 104 (2): 234-240.




2020     |     www.medigraphic.com